This article and associated images are based on a poster originally authored by Banushee Kumar, Alisa Alekseenko, Carmen Navarro and Simon Elsässer and presented at ELRIG Drug Discovery 2025 in affiliation with Epigenica AB and Karolinska Institutet.
This poster is being hosted on this website in its raw form, without modifications. It has not undergone peer review but has been reviewed to meet AZoNetwork's editorial quality standards. The information contained is for informational purposes only and should not be considered validated by independent peer assessment.
Introduction
Epigenetic remodelling is a hallmark of aging and cancer, with DNA methylation (DNAme) and histone post-translational modifications (hPTMs) driving gene regulation, disease onset, and therapeutic response. In cancer, these mechanisms shape tumor initiation, progression, and resistance, while in aging, integrating hPTMs with DNAme may strengthen molecular clock predictions.
Despite the value of epigenetic marks as biomarkers and therapeutic targets in precision medicine, methods for jointly profiling multiple layers remain limited, particularly in their scalability.
The EpiFinder™ platform overcomes these limitations by enabling simultaneous, high-throughput analysis of multiple histone modifications and DNA methylation within a single workflow.
- High-throughput
- Multiplexed
- Quantitative
- Streamlined workflow
- Low technical variability
Technology
Image Credit: Image courtesy of Banushee Kumar et al., in partnership with ELRIG (UK) Ltd.
Product range
Source: ELRIG (UK) Ltd.
|
Genome |
Global |
cNUC |
| Sample Type |
Native or cross-linked
cells Tissue |
Native or cross-linked
cells Tissue |
Plasma,
Serum |
| Throughput |
24 samples x
8 targets |
96 samples x
12 targets |
24 samples x
6 targets |
| Targets |
Histone PTMs,
DNAme, TFs |
Histone PTMs,
DNAme |
Histone PTMs,
DNAme |
Starting material
per sample |
0.5 - 1
million cells |
0.5 - 1
million cells |
0.2 - 1
mL |
Sequencing
depth |
10 - 50 M
reads/sample |
50 - 100 M
reads in total |
5-10 M reads/
sample |
|
|
Coming soon! |
|
Powering precision epigenomics
EpiFinder™ delivers high-throughput, multiplexed epigenome profiling across cell lines, tissues, and liquid biopsies. Its flexible workflow can support treatment comparisons, biomarker discovery, enriching aging-clock models, and therapeutic evaluation in both cancer and aging.
EpiFinder™ genome
EpiFinder™ Genome enables accurate quantification of drug-induced epigenetic changes at both global and locus-specific resolution.
Left: Experimental setup: K562 cells treated with SAHA (4 doses + DMSO control); triplicates of each pooled and processed. Center: SAHA dose–response curve shows global histone acetylation changes. Right: Genome browser (IGV) tracks from combined data across all 15 samples show expected mark enrichment. Image Credit: Image courtesy of Banushee Kumar et al., in partnership with ELRIG (UK) Ltd.
Left: Experimental setup: HEK293T cells treated with SAHA or 5-Aza (+DMSO control); triplicates of each pooled and processed. Center: 5-Aza, DNMT inhibitor reduces global DNA methylation (5mC)5mC, especially at CpG islands. Right: SAHA, HDAC inhibitor increases global H3K27ac and enrichment at TSSs. Image Credit: Image courtesy of Banushee Kumar et al., in partnership with ELRIG (UK) Ltd.
EpiFinder™ cNUC
EpiFinder™ cNUC offers simultaneous profiling of histone PTMs & DNA methylation across plasma samples from multiple individuals.
Image Credit: Image courtesy of Banushee Kumar et al., in partnership with ELRIG (UK) Ltd.
Method precision: Replicate correlations of mean H3K4me3 signal (RPGC-normalized) over TSSs in plasma samples from a cancer patient (left) and a healthy donor (right). Each replicate from 0.5 ml plasma. Image Credit: Image courtesy of Banushee Kumar et al., in partnership with ELRIG (UK) Ltd.
EpiFinder™ cNUC offers simultaneous profiling of histone PTMs & DNA methylation across plasma samples from multiple individuals.'
Image Credit: Image courtesy of Banushee Kumar et al., in partnership with ELRIG (UK) Ltd.
References
- Adalsteinsson, V.A., et al. (2017). Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications, [online] 8(1), pp.1–13. https://doi.org/10.1038/s41467-017-00965-y.
- Love, M.I., Huber, W. and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12), p.550. https://doi.org/10.1186/s13059-014-0550-8.
- Schematic figures created in https://BioRender.com
About Epigenica 
Epigenica is a life sciences technology company driving innovation in epigenetic research. Its flagship EpiFinder platform enables rapid, scalable, and cost-effective epigenetic studies, supporting researchers with a new level of accessibility and precision.
About ELRIG (UK) Ltd.
The European Laboratory Research & Innovation Group (ELRIG) is a leading European not-for-profit organization that exists to provide outstanding scientific content to the life science community. The foundation of the organization is based on the use and application of automation, robotics and instrumentation in life science laboratories, but over time, we have evolved to respond to the needs of biopharma by developing scientific programmes that focus on cutting-edge research areas that have the potential to revolutionize drug discovery.
Comprised of a global community of over 12,000 life science professionals, participating in our events, whether it be at one of our scientific conferences or one of our networking meetings, will enable any of our community to exchange information, within disciplines and across academic and biopharmaceutical organizations, on an open access basis, as all our events are free to attend!
Our values
Our values are to always ensure the highest quality of content, that content will be made readily accessible to all, and that we will always be an inclusive organization, serving a diverse scientific network. In addition, ELRIG will always be a volunteer-led organization, run by and for the life sciences community, on a not-for-profit basis.
Our purpose
ELRIG is a company whose purpose is to bring the life science and drug discovery communities together to learn, share, connect, innovate and collaborate, on an open access basis. We achieve this through the provision of world-class conferences, networking events, webinars, and digital content.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.
Last Updated: Nov 27, 2025